Oral biologic shows promise in RA

A highly anticipated RA treatment has demonstrated its efficacy in patients for whom conventional DMARDs either did not work or weren’t tolerated.

Baricitinib is a selective JAK1 and 2 inhibitor which is now being tested in four global phase 3 trials. The current study randomised nearly 700 patients with moderate to severe RA who were refractory to conventional therapy to once daily doses of either baricitinib 2mg, 4mg, or placebo.

Latest

Trending